Immunoglobulin Market Size, Share and Industry Analysis By Route of Administration (Intravenous (IV), Subcutaneous (SC)), By Indication (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN)), By Form (Liqui, Lyophilized), By End User (Hospitals, Clinics, Homecare), and Regional Forecast 2020-2029 (Includes COVID-19 Business Impact)

                                          
We have updated Immunoglobulins Market with respect to COVID-19 Business Impact.
Inquire before buying


This report focuses on the Immunoglobulins market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Immunoglobulins market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.


Global Immunoglobulins Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.


Global Immunoglobulins Market: Regional Analysis


The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.


Global Immunoglobulins Market: Competitive Landscape


This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

  
Shire (Takeda Pharmaceutical Company Limited)
  
CSL Behring
  
Grifols, S.A.
  
Kedrion S.p.A
  
Octapharma
  
Bio Products Laboratory Ltd.
  
Biotest AG
  
China Biologic Products Holdings, Inc.
  
LFB SA
  
Shanghai RAAS Blood Products Co., Ltd.

Report Coverage

Immunoglobulins, also referred to as antibodies, are the glycoprotein molecules manufactured by the plasma or the white blood cells. Immunoglobulins form a very critical line of defense of the immune system by specially recognizing and binding itself to particular antigens such as bacteria and viruses and aid in their destruction. In certain individuals, these products have to be administered for the treatment and management of diseases such as primary immunodeficiency (PI). However, comparatively high product costs and the associated adverse effects, are some of the major factor projected to restrain the adoption of these products in emerging countries.

The report provides qualitative and quantitative insights on immunoglobulin industry trends and detailed analysis of market size & growth rate for all possible segments in the market. The immunoglobulin market segments include route of administration, indication, form, and end user. On the basis of indication, the market is categorized into (primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barre syndrome (GBS), immune thrombocytopenic purpura (ITP), multifocal motor neuropathy (MMN) and others).

On the basis of route of administration, the market is categorized into intravenous (IV) and subcutaneous (SC). On the basis of form, the market can be segmented into liquid and lyophilized. On the basis of end user, the market can be segmented into hospitals, clinics and homecare. Geographically, the market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The regions are further categorized into countries.
Along with this, the report analysis comprises of market dynamics and competitive landscape. Additionally, the report offers insights on the pipeline analysis, overview of regulatory scenario by key regions, key industry developments, number of primary immunodeficiency (PI) patients by key countries and reimbursement scenario.

SEGMENTATION

By Route of Administration

  
Intravenous (IV)
  
Subcutaneous (SC)

By Indication

  
Primary Immunodeficiency
  
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  
Guillain-Barre Syndrome (GBS)
  
Immune Thrombocytopenic Purpura (ITP)
  
Multifocal Motor Neuropathy (MMN)
  
Others

By Form

  
Liquid
  
Lyophilized

By End User

  
Hospitals
  
Clinics
  
Homecare

By Geography

  
North America (the U.S., and Canada)
  
Europe (Germany, U.K., France, Italy, Spain, Scandinavia, and Rest of Europe)
  
Asia Pacific (China, India, Japan, Australia, South East Asia, and Rest of Asia Pacific)
  
Latin America (Brazil, Mexico, and Rest of Latin America
  
Middle East & Africa (GCC, South Africa, and Rest of Middle East & Africa)

Key Industry Developments

In May 2019, the FDA approved the prior approval supplement (PAS) for ADMA Biologics, Inc.s product offering of BIVIGAM and subsequently ADMA announced that it will begin the commercial sales of the product

In April 2019, a novel intravenous immunoglobulin by ADMA Biologics, Inc. to be utilised for the treatment of primary immunodeficiency called Asceniv (Immune Globulin Intravenous, Human -slra 10%, Liquid), received the FDA approval

In May 2018, Kedrion S.p.A and Kamada announced that KEDRAB, an immunoglobulin aimed at the treatment of rabies, was ready for commercial distribution and shipping